GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Cyclically Adjusted Book per Share

Silence Therapeutics (Silence Therapeutics) Cyclically Adjusted Book per Share : $9.01 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Silence Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was $3.380. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.01 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Silence Therapeutics's average Cyclically Adjusted Book Growth Rate was -40.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-11), Silence Therapeutics's current stock price is $20.79. Silence Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $9.01. Silence Therapeutics's Cyclically Adjusted PB Ratio of today is 2.31.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 4.59. The lowest was 0.13. And the median was 0.52.


Silence Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Silence Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Cyclically Adjusted Book per Share Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 24.83 28.72 42.85

Silence Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.04 29.97 57.43 42.85 9.01

Competitive Comparison of Silence Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Silence Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cyclically Adjusted PB Ratio falls into.



Silence Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Silence Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.38/131.6000*131.6000
=3.380

Current CPI (Mar. 2024) = 131.6000.

Silence Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
200806 35.000 86.600 53.187
200812 25.000 87.100 37.773
200906 21.554 88.100 32.196
200912 16.072 88.900 23.792
201006 27.621 90.200 40.298
201012 27.139 91.700 38.948
201106 23.731 93.500 33.401
201112 16.105 95.000 22.310
201206 3.260 95.600 4.488
201212 3.967 97.300 5.365
201306 3.704 98.000 4.974
201312 3.087 99.200 4.095
201406 3.449 99.800 4.548
201412 2.584 99.900 3.404
201506 4.988 100.100 6.558
201512 4.239 100.400 5.556
201606 3.509 101.000 4.572
201612 2.907 102.200 3.743
201706 2.668 103.500 3.392
201712 3.010 105.000 3.773
201806 2.504 105.900 3.112
201812 1.893 107.100 2.326
201906 1.450 107.900 1.768
201912 1.094 108.500 1.327
202006 1.287 108.800 1.557
202009 0.000 109.200 0.000
202012 0.438 109.400 0.527
202103 0.000 109.700 0.000
202106 1.110 111.400 1.311
202109 0.751 112.400 0.879
202112 0.379 114.700 0.435
202203 0.176 116.500 0.199
202206 -0.195 120.500 -0.213
202209 1.077 122.300 1.159
202212 0.748 125.300 0.786
202303 0.559 126.800 0.580
202306 0.421 129.400 0.428
202309 0.640 130.100 0.647
202312 0.545 130.500 0.550
202403 3.380 131.600 3.380

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Silence Therapeutics  (NAS:SLN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Silence Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=20.79/9.01
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 4.59. The lowest was 0.13. And the median was 0.52.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Silence Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.